Failure of initial therapy with two nucleosides and efavirenz is not associated with early emergence of mutations in the C-terminus of HIV-1 reverse transcriptase

Journal of Acquired Immune Deficiency Syndromes

Volumn 56, Issue 4, 2011, Pages 344-348

  Brehm, Jessica H ^a,b   Lalama, Christina M ^c   Hughes, Michael D ^c   Haubrich, Richard ^d   Riddler, Sharon A ^b   Sluis Cremer, Nicolas ^b   Mellors, John W ^b  

^a UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

efavirenz; HIV 1 drug resistance; HIV 1 reverse transcriptase; nucleoside and nonnucleoside RT inhibitors; RT connection domain; RT RNase H domain

Indexed keywords

EFAVIRENZ; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; RIBONUCLEASE H; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR DISOPROXIL; VIRUS RNA;

AMINO ACID SEQUENCE; ARTICLE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; DRUG EFFICACY; DRUG TREATMENT FAILURE; GENETIC ASSOCIATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MUTATION RATE; MUTATIONAL ANALYSIS; NONHUMAN; NUCLEOTIDE SEQUENCE; OPEN STUDY; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VIRUS LOAD; VIRUS MUTATION;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BENZOXAZINES; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; MUTATION, MISSENSE; NUCLEOSIDES; RNA, VIRAL; SEQUENCE ANALYSIS, DNA;

EID: 79952419158     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e31820cf029     Document Type: Article

References (19)

1. Wang J, Smerdon SJ, Jager J, et al. Structural basis of asymmetry in the human immunodeficiency virus type 1 reverse transcriptase heterodimer. Proc. Natl. Acad. Sci. USA. 1994;91:7242-7246. (Pubitemid 24226839)
2. Johnson VA, Brun-Vezinet F, Clotet B, et al. Update of the Drug Resistance Mutations in HIV-1. Top HIV Med. 2008;16:138-145.
3. Cane PA, Green H, Fearnhill E, et al. Identification of accessory mutations associated with high-level resistance in HIV-1 reverse transcriptase. AIDS. 2007;21:447-455.
4. Hachiya A, Kodama EN, Sarafianos SG, et al. Amino acid mutation N348I in the connection subdomain of human immunodeficiency virus type 1 reverse transcriptase confers multiclass resistance to nucleoside and nonnucleoside reverse transcriptase inhibitors. J Virol. 2008;82:3261-3270. (Pubitemid 351429905)
5. Hachiya A, Shimane K, Sarafianos SG, et al. Clinical relevance of substitutions in the connection subdomain and RNase H domain of HIV-1 reverse transcriptase from a cohort of antiretroviral treatment-naive patients. Antiviral Res. 2009;82:115-121.
6. Kemp SD, Shi C, Bloor S, et al. A novel polymorphism at codon 333 of human immunodeficiency virus type 1 reverse transcriptase can facilitate dual resistance to zidovudine and L-2',3'-dideoxy-3'-thiacytidine. J Virol. 1998;72:5093-5098. (Pubitemid 28215690)
7. Nikolenko GN, Delviks-Frankenberry KA, Palmer S, et al. Mutations in the connection domain of HIV-1 reverse transcriptase increase 3'-azido- 3'-deoxythymidine resistance. Proc Natl Acad Sci USA. 2007;104:317-322. (Pubitemid 46068029)
8. Ntemgwa M, Wainberg MA, Oliveira M, et al. Variations in reverse transcriptase and RNase H domain mutations in human immunodefi- ciency virus type 1 clinical isolates are associated with divergent phenotypic resistance to zidovudine. Antimicrob Agents Chemother. 2007; 51:3861-3869. (Pubitemid 350057782)
9. Roquebert B, Wirden M, Simon A, et al. Relationship between mutations in HIV-1 RNase H domain and nucleoside reverse transcriptase inhibitors resistance mutations in naive and pre-treated HIV infected patients. J Med Virol. 2007;79:207-211. (Pubitemid 46213183)
10. Santos AF, Lengruber RB, Soares EA, et al. Conservation patterns of HIV- 1 RT connection and RNase H domains: identification of new mutations in NRTI-treated patients. PLoS ONE. 2008;3:e1781.
11. Yap SH, Sheen CW, Fahey J, et al. N348I in the connection domain of HIV-1 reverse transcriptase confers zidovudine and nevirapine resistance. PLoS Med. 2007;4:e335.
12. Waters JM, O'Neal W, White KL, et al. Mutations in the thumb-connection and RNase H domain of HIV type-1 reverse transcriptase of antiretroviral treatment-experienced patients. Antivir Ther. 2009;14:231-239.
13. von Wyl V, Ehteshami M, Demeter LM, et al. HIV-1 reverse transcriptase connection domain mutations: dynamics of emergence and implications for success of combination antiretroviral therapy. Clin Infect Dis. 2010;51: 620-628.
14. Gupta S, Fransen S, Paxinos EE, et al. Combinations of mutations in the connection domain of human immunodeficiency virus type 1 reverse transcriptase: assessing the impact on nucleoside and nonnucleoside reverse transcriptase inhibitor resistance. Antimicrob Agents Chemother. 2010;54:1973-1980.
15. Sluis-Cremer N, Moore K, Radzio J, et al. N348I in HIV-1 reverse transcriptase decreases susceptibility to tenofovir and etravirine in combination with other resistance mutations. AIDS. 2010;24:317-319.
16. Gotte M. Should we include connection domain mutations of HIV-1 reverse transcriptase in HIV resistance testing. PLoS Med. 2007;4:e346.
17. Roquebert B, Marcelin AG. The involvement of HIV-1 RNAse H in resistance to nucleoside analogues. J Antimicrob Chemother. 2008;61: 973-975. (Pubitemid 351524436)
18. Riddler SA, Haubrich R, DiRienzo AG, et al. Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med. 2008;358:2095-2106. (Pubitemid 351679596)
19. John M, Heckerman D, James I, et al. Adaptive Interactions between HLA and HIV-1: highly divergent selection imposed by HLA class I molecules with common supertype motifs. J Immunol. 2010;184:4368-4377.